Additional file 2: of Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation

Figure S1. Bortezomib inhibits TRAF6-mediated Akt activation. Figure S2. Combined treatment synergistically inhibits tumorigenesis of human oral cancer cells in vivo. (DOCX 2226 kb)